Huda Salah Eldin: The Challenge of Balancing Antithrombotic Therapy After PCI
Huda Salah Eldin, Certified traineer in clinical pharmacy and critical care at Egyption health council at Egyption Health Council, shared a post on LinkedIn:
“One of the most challenging situations we faced in the CCU: balancing antiplatelet therapy and anticoagulation after PCI.
A patient with a recent myocardial infarction (MI) undergoes PCI with stent placement and requires dual antiplatelet therapy (DAPT).
But what if the patient also has an indication for long-term oral anticoagulation, such as atrial fibrillation (AF) or venous thromboembolism requiring extended treatment?
Combining these medications increases bleeding risk-making the choice and duration of therapy crucial.
The 2023 ESC guidelines for acute coronary syndromes outline an approach tailored to each patient’s ischaemic and bleeding risks:
1.Initial phase: Triple therapy
- Oral anticoagulant plus Clopidogrel plus Aspirin
The default duration is up to 1 week. This may be extended to 1 month when the risk of stent thrombosis outweighs the bleeding risk.
2.Next phase: Dual antithrombotic therapy
- Stop Aspirin and continue Oral anticoagulant plus Clopidogrel.
Continue for up to 12 months after the acute event. A shorter duration may be considered in selected patients at high bleeding risk.
3.Beyond 12 months: Anticoagulation alone
- Discontinue Clopidogrel and continue the oral anticoagulant alone in most patients with an ongoing indication.
The goal is always to balance protection against stent thrombosis and thromboembolic events with the risk of bleeding.
An individualised treatment plan – and regular reassessment – makes all the difference.
Which factors most influence your decision about the duration of triple therapy in clinical practice?”

Stay updated with Hemostasis Today.
-
Nov 10, 2026, 16:28Can the VWF to ADAMTS-13 Ratio Predict Mortality in Sepsis-Induced Coagulopathy? – RPTH Journal
-
Nov 10, 2026, 16:28Ruth Willems: PhD Defence at Maastricht University on Thrombosis and Bleeding in HPB Disease
-
Nov 10, 2026, 16:09Edward Lee Carter: Factor XIa Inhibition Enters Clinical Practice
-
Nov 10, 2026, 16:08Edward C.C. Wong: Deriving Ferritin Cutoffs for Iron Deficiency Using RBC Parameters
-
Nov 10, 2026, 16:07Milad Abdalla: Decoding Hemoglobin Electrophoresis – A Practical Diagnostic Reference
-
Nov 10, 2026, 15:13Wolfgang Miesbach: Nonviral Gene Therapy for Haemophilia A Using Lipid Nanoparticles
-
Nov 10, 2026, 15:06Dahra Teles: First Speaking Experience at HEMO 2026 on First-Line Multiple Myeloma Treatment
-
Nov 10, 2026, 14:55Yazan Abou-Ismail: First FDA-Approved Factor XIa Inhibitor for Stroke Prevention
-
Nov 10, 2026, 14:49Ifeanyichukwu Ifechidere: The Role of Coagulation in Anaesthesia and Surgery